Ferroquine/ Artefenomel

Sanofi

Product vision
  • Uncomplicated malaria treatment for single-exposure radical cure (SERC) and/or resistance management

MoA
  • Ferroquine (FQ), belonging to 4-aminoquinolines: inhibition of haem detoxification
  • Artefenomel (OZ439): novel, synthetic trioxolane
Key features

Ferroquine

  • Long duration of plasma exposure

Artefenomel

  • Fast killing of parasites

  • 800mg human dose stays above Minimal Parasiticidal Concentration for >8 days

  • Transmission-blocking activity in a Standard Membrane Feeding Assay

Challenges
  • OZ439 food effect/formulation

Status
  • Two phase II studies were completed in 2020
Next milestone
  • Close out phase IIb program and elaborate plan to develop ferroquine with another partner drug
Previously
  • Ferroquine discovered by CNRS Lille
  •  Artefenomel: discovery partnership between MMV, Monash University, University of Nebraska and Swiss Tropical Institute
MMV Project Director
  • Dr Florian Wartha